BioNanomatrix, a developer of single-molecule genomic analysis technology, has issued US patent 7,670,770 for nanochannel arrays that enable high-throughput macromolecular analysis to Princeton University on March 2, 2010.
BioNanomatrix has also disclosed the methods of preparing nanochannel array chips, methods of analyzing macromolecules such as entire strands of genomic DNA, and systems for implementing these methods.
Single molecule analysis of intact native DNA has been limited by the difficulty of ‘linearizing’ and manipulating these long, complex molecules.
To address the limitations, a Princeton University research team, including Han Cao, developed a simple approach that uses a nano-fluidic chip to untangle and guide individual molecules into an array of nanochannels. The technique is ideally suited for multiplexed parallel processing for applications ranging from direct imaging analysis of structural variations in a person’s genome to DNA mapping and sequencing applications.
The NanoAnalyzer is an integrated system that enables pan-genomic identification and analysis on a molecule-by-molecule basis, delivering single molecule sensitivity in a highly parallel format. It is designed to provide ultra high-resolution analyses of macromolecules, such DNA and proteins, and their interactions more rapidly, comprehensively, and cost effectively than currently available approaches.
Han Cao, founder and chief scientific officer of BioNanomatrix, said: “This patent covers the fundamental method and device for isolating, imaging, and analyzing nucleic acid biopolymers confined within nanoscale fluidic channels. This invention allows for true linear analysis of very long biomolecules such as native genomic DNA hundreds of thousands of base pairs in length without cloning or PCR amplification.
“This transformative technology has single cell and single molecule sensitivity and will open many new opportunities in the biomedical field. We enable the analysis of intact, yet minute, biological samples without tedious processing and complex error-prone reassembly. This technology will change the way we design and do many biomedical experiments and analyses in the future. We are very excited about the official issuance of this key patent, which places BioNanomatrix in the forefront of this emerging field.”
Edward Erickson, president and CEO of BioNanomatrix, said: “Under our license agreement with Princeton University we now have two issued patents. Additionally, the Company itself is currently prosecuting eight families of patents covering many aspects of our NanoAnalyzer system.”